NEOGENOMICS INC (NEO) Q3 2025 10-Q Quarterly Report
NEOGENOMICS INC (NEO) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 28, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
NEOGENOMICS INC Q3 2025 10-Q Analysis
Risk Factors
- • No new risk factors added this quarter; risk profile consistent with 2024 Form 10-K
- • Most materially updated risk: no specific changes disclosed in current 10-Q
- • Regulatory risk: ongoing compliance with evolving FDA and CMS regulations critical for lab services reimbursement
- • Operational risk: dependency on timely integration of acquisitions affecting near-term revenue growth
- • Financial risk: liquidity management pivotal given $100M debt maturing in next 18 months
Get deeper insights on NEOGENOMICS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.